SCHEMBL1663833

SCHEMBL1663833

CC(C)c1nc2cc(O)ccc2c(=O)n1Cc1cccnc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.47
S1PR3 Q99500 1/20 0.45
PRKDC P78527 1/20 0.45
SRC P12931 1/20 0.44
KMT2A Q03164 4/20 0.43
PKM P14618 3/20 0.43
OPRM1 P35372 1/20 0.43
OPRD1 P41143 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
MAPK10 P53779 1/20 0.42
ALOX5AP P20292 1/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 3/20 0.41
RAD1 O60671 1/20 0.41
MAPT P10636 1/20 0.41
CFTR P13569 1/20 0.41
APEX1 P27695 1/20 0.41
CASP6 P55212 1/20 0.41
RAD51 Q06609 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1663625 0.86 TRPV1 (0.50) TRPV1KMT2AHDAC1HDAC6ALOX5AP
SCHEMBL1663990 0.79 TRPV1 (0.47) TRPV1KMT2AHDAC1HDAC6KDM4E
SCHEMBL1666082 0.79 TRPV1 (0.47) TRPV1HDAC1HDAC6ALDH1A1KDM4E
SCHEMBL1663099 0.77 TRPV1 (0.47) TRPV1KMT2AHDAC1HDAC6ALOX5AP
SCHEMBL1663885 0.77 ALOX5AP (0.52) TRPV1KMT2AHDAC1HDAC6ALOX5AP
SCHEMBL1663421 0.77 TRPV1 (0.54) TRPV1HDAC1HDAC6ALDH1A1TLR7
SCHEMBL1664148 0.77 TRPV1 (0.54) TRPV1KMT2AHDAC1HDAC6ALDH1A1
SCHEMBL1663587 0.76 TRPV1 (0.47) TRPV1KMT2AHDAC1HDAC6TLR7
SCHEMBL1663843 0.74 AKR1B1 (0.48) TRPV1KMT2AALDH1A1KDM4EMAPT
SCHEMBL1663306 0.74 TRPV1 (0.51) TRPV1HDAC1HDAC6ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
CN-101356160-A Trisubstituted quinazolinone derivatives as vanilloid antagonists JANSSEN PHARMACEUTICA NV (CH) 2009-01-28 CN disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 TRPV1 1/4885S1PR3 431/4885PRKDC 3492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.